The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

In November 2024, the European Commission approved GSK's single-vial, fully liquid Menveo vaccine (MenACWY). "Muna-GSK ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

【葛兰素史克的液体脑膜炎疫苗获欧盟批准】葛兰素史克(GSK)的液体脑膜炎疫苗Menveo已获得欧盟委员会的批准，可在欧盟销售。这家英国制药公司周三表示，这种全液体疫苗有助于简化针对侵袭性脑膜炎球菌病(IMD)的疫苗接种流程，因为它为医疗健康提供者提供了一种无需在使用前进行复溶的选择。

In November 2024, the European Commission approved GSK’s single-vial, fully liquid Menveo vaccine (MenACWY). Give your business an edge with our leading industry insights. Give your business an edge ...

Teva Pharmaceutical Industries Ltd. ADR 1.56% $20.17B ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix, in ...

GSK managed to beat analysts’ revenue predictions ... backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million ...

with the falls offset partially by gains for its meningitis jabs Bexsero and Menveo, which rose 22% to £520 million. Overall, vaccine sales were down 15%, and GSK cut its forecast for the ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...